Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.

"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super ...

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...